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Autoimmune epilepsies are a heterogeneous group of recently
described refractory epilepsies. They have been characterized by a
variety of clinical, serological and radiological features. A range of
anti-neuronal antibodies, which are usually found in limbic
encephalitis, including antibodies to GAD,1–4 VGKC-complex
antibodies,5–11 NMDA-R,12–14 amongst others, have been associ-
ated with some of these disorders. Other, antibody negative
epilepsy patients had radiological features of central nervous
system inﬂammation, inﬂammatory inﬁltrates histologically or
high CSF white cell counts and oligoclonal bands.11 Immune
therapy, including steroids and IVIg, has been used in these cases
and resulted in clinical improvement. Best outcomes were
associated with a short duration of the underlying illness.5,12
Long-term immune therapy has often been utilized in these cases.
In this article, we describe a small cohort of patients who had a
rapid, sustained response to a short course of IVIg, despite limitedAbbreviations: ACTH, adrenocorticotrophic hormone; AEDs, antiepileptic drugs;
CSF, cerebrospinal ﬂuid; CT, computer tomography; DZP, diazepam; EEG,
electroencephalogram; FDG-PET, ﬂurodecarboxyglucose – positron emission
tomography; GAD, glutamic acid decarboxylase; GGE, genetic generalized epilepsy;
IVIg, intravenous immunoglobulins; LEV, levetiracetam; LTG, lamotrigine; MRI,
magnetic resonance tomography; NMDA-R, N-methyl-di-aspartase receptor; OxC,
oxcarbazepine; PB, phenobarbitone; PHT, phenytoin; RE, Rasmussen’s encephalitis;
SIADH, syndrome of inappropriate antidiuretic hormone secretion; TPM, topir-
amate; VGB, vigabatrin; VGKC, voltage-gated potassium channel; VPA, valproic
acid.
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mune process. This response was independent of the varying
seizure phenotypes. Interestingly, all 3 patients shared a certain
EEG pattern.
2. Case 1
A 17 year old right handed girl, with a diagnosis of juvenile
myoclonic epilepsy, was transferred in super-refractory status
epilepticus of 3 days duration. Seizure semiology comprised
ongoing episodes of alternating left and right sided facial jerking,
eye deviation to the right, unresponsiveness and audible shallow
breaths. These focal episodes frequently evolved to generalized
tonic-clonic seizures. Despite escalating treatment in an ICU
setting with intubation and anaesthetic agents, using high doses of
LTG, LEV, TPM, VPA, PHT, clobazam, midazolam, magnesium and
propofol infusions, she had ongoing seizures after 11 days.
EEG showed alternating left and right hemispheric epileptiform
discharges with simultaneous contralateral frontal spike wave
activity (Fig. 1a).
Because of the hemispheric emphasis of the epileptiform
discharges, reminiscent of Rasmussen’s encephalitis, a treatment
attempt with IVIg, at a dose of 0.4 g/kg/day for 5 days, was
undertaken. Twelve hours after the ﬁrst dose of IVIg, the seizures
had terminated clinically, but she remained confused and drowsy.
An EEG at this stage showed generalized slowing (Fig. 1b). An MRI
performed at this point was normal. By Day 15, the patient had
made a full recovery and was sitting in bed doing her homework.
Her EEG had completely normalized (Fig. 1c). Anti-thyroid
antibodies (serum collected prior to initiation of IVIG) returned
as mildly positive (Table 1).
She was discharged a week later and followed up in the clinic at
1, 3, 6 and 15 months. Repeat MRI head and EEG at 3 months post
discharge were normal. No further IVIg has been administered. Her
current AED regimen has been reduced to monotherapy with LTG
100 mg BD. No further seizures have been reported by the patient
or her family.
Prior to this episode, she was thought to have a generalized
epilepsy syndrome on the basis of a positive family history (the
parents are ﬁrst cousins and there is a history of epilepsy in the
maternal grandmother), a history of absences and upper limbvier Ltd. All rights reserved.
Fig. 1. (a) Case 1 – EEG, day 9 of super-refractory status epilepticus. Bipolar 10-20 montage of ongoing left hemispheric and bi-frontal polyspike and 2.5–3 Hz spike-wave
epileptiform discharges. (b) Case 1 – EEG 12 h post IVIg – referential average montage showing generalized slowing. (c) Case 1 – EEG post 5 days IVIg. Return of normal trace.
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generalized spike and polyspike and wave activity.
She had a past history of three admissions, at the ages of 6
months, 9 months and 2 years, to intensive care units with
refractory status epilepticus (including one episode of epilepsia
partialis continua aged 2 years old). Each episode lasted between 2
and 15 days. Ictal EEGs were reported to show continuous 4–5 Hz
spike and polyspike and wave activity, which on variousadmissions occurred either independently over both hemispheres
or unilaterally over either the right or left hemisphere. Treatment
was reported to have been difﬁcult and required midazolam
infusions, nitrazepam, paraldehyde, PB, PHT and ACTH in various
combinations.
Maintenance therapy initially consisted of VGB and PHT with
poor control. Later, after addition of LTG, the patient became
seizure-free for 5 years on monotherapy.
Table 1
Overview of clinical investigation results.
Findings Patient 1 Patient 2 Patient 3
Auto-antibodies - Anti-thyroid peroxidase
antibodies 249 IU/ml
- Anti-thyroglobulin
- Antibodies 144 IU/ml
- ANA + 1:160
- Negative: VGKC-complex,
GAD, NMDA Abs, LGI-1 Abs,
CASPR2 Ab, ENA
-ANA 40+, negative ENA
-Negative: VGKC-complex, NMDA Abs,
LGI-1 Abs, GAD, CASPR2
Positive immunoﬂuorescence of patient’s
serum on mouse brain showing a cytoplasmic
staining pattern of cerebellar Purkinje cells;
no target antigen was identiﬁable on
Immunoblot (Euroimmun)
Genetic studies - PCDH19 – negative Not done Not done
- Pol G – negative
- Ring chromosome 20 – negative
Hormonal studies TFTs - normal Cortisol (random) 793 nmol/l -
TFTs – normal
SIADH:
- Serum sodium 120 mmol/l
- Serum osmolality 250 mmol/l
- Urine sodium 70 mmol/l
- Urine osmolality 362 mmol/kg
CSF - Protein 230 Refused by patient Protein 260
- WCC 1 WCC 65
- Glucose 3.3 Glucose 2.8
- No oligoclonal bands No oligoclonal bands
MRI brain Normal Normal Post surgical changes to left temporal lobe.
No other features.
PET scan Normal – full body Normal Not performed
Further imaging Ultrasound thyroid & pelvis – normal CT thorax/abdomen/pelvis – normal CT thorax/abdomen/pelvis – normal
Further investigations - Skin biopsy – normal - Histology of temporal lobe
resection (1992) – gliosis
- Muscle biopsy (aged 6 months) – normal
- Audiometry – normal
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months of age, she was an average student and had aspirations of
becoming a teacher.
Over the years, she had multiple negative investigations for
underlying causes of the epileptic syndrome, including multiple
genetic, immunological and metabolic tests (Table 1).
3. Case 2
A 69 year old female with a history of bipolar affective disorder
(currently untreated) and ischaemic heart disease presented to our
hospital in focal status epilepticus. There was no previous history
of epilepsy. She had a two day history of confusion, epilepsia
partialis continua comprising left-sided jerking movements
involving her head, shoulder, arm, abdominal muscles and leg
with occasional brief generalized tonic-clonic seizures. She had
transient hyponatremia (120 mmol/l) in keeping with SIADH;
other investigations, including a range of neuroimaging and
serological studies and screens for malignancy was normal
(Table 1). Consent for a lumbar puncture was not given.
In spite of treatment with high-dose PHT, DZP, LEV, VPA and
TPM she had ongoing seizures for 48 h. An EEG showed right
hemispheric rhythmic spike and spike wave activity, with very
infrequent left frontal sharp waves (Fig. 2a).
IVIg at a dose of 0.4 g/kg/day for 5 days was started. 12–15 h
after the ﬁrst dose there was complete resolution of the clinical
events. By day 2 (post second dose) her confusion resolved and the
EEG changes had normalized (Fig. 2b). Despite stopping of all AEDs
against medical advice and with no further administration of IVIg,
she continues to be seizure free at 12 months.
4. Case 3
A 42 year old male, was admitted with multiple seizures. He had
a past history of encephalitis at the age of three and developedrecurrent seizures at the age of nine. These seizures were refractory
focal seizures with dyscognition, comprising an aura of a rising
epigastric sensation followed by vocalization and evolution to
generalized tonic clonic activity and post-ictal aggression. These
occurred approximately two to three times a week. He also
reported frequent isolated auras. At age 22, he underwent
evaluation for epilepsy surgery. Scalp EEG recordings revealed
occasional left hemispheric discharges, with an emphasis over the
fronto-temporal region. His epilepsy was refractory to PHT, CBZ,
OxC, LTG, LEV, PB, and clobazam.
In 1992, he underwent intracranial EEG recording and ﬁnally
proceeded to left anterior amygdalohippocampectomy. Histologi-
cal examination revealed gliosis, without any evidence of
inﬂammation or malignancy. Surgery resulted in seizure freedom
for 9 months. Later, seizure frequency drastically increased with
numerous auras per day, second-daily focal seizures and weekly
secondarily generalized tonic-clonic seizures. He was maintained
on LEV and LTG and did not attend follow up appointments.
He was admitted to hospital after trauma, but was noted to have
multiple seizures with post-ictal aggression. As his EEG showed
similarities with the previously described cases – frequent uni-
hemispheric epileptiform discharges with contralateral frontal
spikes (Fig. 3a) – a treatment trial with IVIg at a dose of 0.4 g/kg for
5 days was commenced, without any other alteration in his AED
regime. With this, his EEG remained unchanged. However, by day 2
he had no further seizures and remained completely seizure free
for 4 months. He subsequently represented with 2 further seizures
and was successfully treated again with 5 days of IVIg and monthly
maintenance therapy. Currently, he experiences mild focal
seizures with dyscognition, approximately once every 3 months,
which represents a signiﬁcant decrease in seizure frequency and
cessation of tonic-clonic seizures. Of note, his EEG signiﬁcantly
improved after 6 months of treatment, with infrequent epilepti-
form discharges, detected only by prolonged EEG monitoring
(Fig. 3b).
Fig. 2. (a) Case 2 – EEG during focal status epilepticus: Bipolar 10-20 montage EEG with right hemisphere continuous epileptiform discharges at 2 Hz and infrequent left
frontal spikes. (b) Case 2 – EEG post treatment with 2 doses of IVIg.
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Oligoclonal bands were not detected. Immunoﬂuorescence studies
of the patient’s serum on mouse brain revealed a cytoplasmic
staining pattern of cerebellar Purkinje cells, but no target antigen
was identiﬁable on Immunoblot (Euroimmun); its pathophysio-
logical signiﬁcance is unclear. MRI brain showed only old left
temporal post-surgical changes. Testing for other anti-neuronal
antibodies (VGKC-complex, NMDA-R) were negative (Table 1).
5. Discussion
IVIg has been investigated for refractory epilepsy in the past in a
number of small studies and case series with variable effect.15 The
EFNS guidelines have recommended IVIg use in the setting of
speciﬁc syndromes (RE, West syndrome, Landau-Kleffner syn-
drome).16
In recent years, a heterogeneous group of immune mediated
epilepsies has been described, based on the presence of a number
of anti-neuronal antibodies (VKGC-complex, NMDA-R, GAD, etc.),
inﬂammatory changes in CSF and neuroimaging.1,2,5,11,17,18 A
subgroup of these patients responded to IVIg.
Furthermore, IVIg has found new favour in the setting of super-
refractory status epilepticus. However, it appears to be utilized
when conventional treatment with AEDs has been exhausted and
in the absence of markers of underlying autoimmunity.19 A recent
Cochrane review has found no clear evidence for efﬁcacy of IVIg as
a treatment for refractory epilepsy.20This paper describes a case series of patients with refractory
epilepsy, who, whilst presenting heterogeneously in terms of
clinical features and seizure types, had all a quick and sustained
response to IVIg. Common to all 3 cases was a certain EEG pattern,
namely unihemispheric epileptic discharges with contralateral
frontal involvement, but without clear focal features. Based on this
EEG pattern combined with the scenario of AED refractory seizures,
a treatment trial with IVIg was commenced.
Even though none of our cases has RE, this EEG pattern draws
parallels to it. RE is a hemispheric encephalitis which is widely
believed to have an autoimmune basis. Progression is slowed with
immunomodulatory treatment.21,22 The EEG in RE evolves over
time, initially comprising lateralized epileptiform discharges from
the affected hemisphere, and progressing to multifocal contralat-
eral epileptiform discharges later in the disease course – termed
‘‘false lateralisation’’.23,24 Other syndromes sharing this pattern
include Sturge–Weber, focal cortical dysplasia, hemiconvulsion-
hemiplegia-epilepsy-syndrome and PCDH19 related epilepsies.
None of these ﬁt our cases.
None of our cases have a previous personal or family history of
autoimmunity or cognitive impairment. Indeed, Case 3 is the only
case in this series with strong clinical evidence of an autoimmune
process (CSF pleocytosis, anti-neuronal antibodies). The progres-
sion of the EEG over time, in this case, is worth noting. Initially,
pre-operative monitoring reported a predominantly focal area over
the left fronto-temporal region, however, with infrequent left
hemisphere discharges. Years later, on presentation to our
service, sustained left hemisphere, epileptiform discharges, with
Fig. 3. (a) Case 3 – Interictal EEG. Continuous 2 Hz left hemispheric and right frontal epileptiform discharges. (b) Case 3 – EEG 6 months post IVIg treatment. Marked
improvement in EEG. Infrequent right hemisphere discharges seen only during prolonged EEG monitoring.
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ment came a marked improvement in the EEG with infrequent
epileptiform discharges, captured only during prolonged EEG
telemetry. The progression of this EEG is similar to the changes
seen in RE.
Case 1 represents the ﬁrst reported case of a genetic generalized
epilepsy with a probable immune component manifesting as
super-refractory status epilepticus, responding to IVIg. Although
some studies have alluded to a possible link between GGE and
autoimmunity,2,25 it is often in the context of other autoimmune
disorders and not in isolated GGE. Interestingly, the patient
maintained the spike-wave hallmarks of genetic generalized
epilepsy, but with the pattern described in this article.
In contrast to previously reported cases of autoimmune
epilepsies, the decision to treat with IVIg depended predominantly
upon this EEG pattern, rather than more classical markers of CNS
autoimmunity (anti-neuronal antibodies, CSF inﬂammatory mar-
kers, neuro-imaging).The quick and sustained response of IVIg in
our patients is remarkable. Multiple mechanisms of IVIg, including
immediate and long-lasting effects have been proposed. These
included inhibition of inﬂammatory cytokines and neutralization
of pathogenic antibodies, as well as long-term inactivation and
apoptosis of both autoreactive T and B cells.26–28
A similar rapid and sustained response to IVIg can also be seen
in ITP and NMDA-R encephalitis. In ITP, this is mediated by
enhancement of suppressor T lymphocyte function and a decrease
in autoantibody production.29,30 Whilst the evidence for an auto-
immune process in our cases is poor, this might would be a possible
explanation for the ongoing remission in 2 of our 3 cases withoutfurther treatment with IVIg.Another mechanism that may have
contributed to seizure freedom in our cases is the ability of IVIg to
decrease permeability of the blood–brain barrier. This is an
important function in refractory status epilepticus, where inﬂux of
pro-convulsive albumin into the CNS parenchyma occurs.31 IVIg
also prevents entry of immune cells and antibodies into the CNS, by
blocking extracellular matrix proteins.26–28
Although we contemplated the addition of steroids, the use of
IVIg monotherapy led to a rapid, impressive clinical response in
these cases. Although we cannot be sure if steroids would have
worked, the literature does suggest that steroids as monotherapy
appear less effective in autoimmune encephalitides,12 possibly due
to the broader mechanism of action of IVIg. In the third patient, IVIg
was used immediately because of pattern recognition of the EEG
and our previous experiences.
In summary, we describe 3 cases with a characteristic, but non-
speciﬁc EEG pattern, which responded to treatment with IVIg. We
wonder whether this EEG pattern has been seen in other cases of
immune responsive epilepsy. If these EEG ﬁndings can be
reproduced in larger studies, this could have signiﬁcant clinical
implications, most notable in the setting of refractory status
epilepticus.
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